Now, is NVAX stock poised to rise from here? Now, is NVAX stock poised to grow? Covid-19 vaccine developer Novavax’s stock (NASDAQ: NVAX) remained flat over the last week, compared to the broader Nasdaq-100 which declined by about 3%, amid concerns of surging U.S. inflation and the coming interest rate hikes.